Stock Track | Myriad Genetics Soars 5% as MyRisk Cancer Test Expands to Include 15 New Actionable Genes

Stock Track11-10

Shares of Myriad Genetics (NASDAQ: MYGN) are soaring 5.00% in Monday's intraday trading session following the company's announcement of a significant expansion to its MyRisk® Hereditary Cancer Test. The molecular diagnostic testing leader has added 15 new clinically actionable genes to the test, bringing the total to 63 genes across more than 11 cancer types.

The expanded MyRisk test now includes 100% of the genes strongly recommended by national oncology guidelines, including those from the National Comprehensive Cancer Network (NCCN) and the American Society of Clinical Oncology (ASCO). This enhancement is designed to provide more comprehensive genetic information to guide cancer treatment decisions, surveillance planning, and family risk assessment.

Dale Muzzey, Ph.D., Chief Scientific Officer at Myriad Genetics, emphasized the importance of this expansion, stating, "While many labs can detect DNA variants, it's the interpretation of those variants that truly impacts patient care and that is where Myriad excels." The company's focus on including genes that influence treatment decisions aligns with medical society recommendations, potentially strengthening Myriad's position in the competitive genetic testing market.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1118188568?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-10 23:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1118188568","market":"sg","top_or_hot":-1,"title":"Stock Track | Myriad Genetics Soars 5% as MyRisk Cancer Test Expands to Include 15 New Actionable Genes","media":"Stock Track","content":"<p>Shares of Myriad Genetics (NASDAQ: MYGN) are soaring 5.00% in Monday's intraday trading session following the company's announcement of a significant expansion to its MyRisk® Hereditary Cancer Test. The molecular diagnostic testing leader has added 15 new clinically actionable genes to the test, bringing the total to 63 genes across more than 11 cancer types.</p>\n\n<p>The expanded MyRisk test now includes 100% of the genes strongly recommended by national oncology guidelines, including those from the National Comprehensive Cancer Network (NCCN) and the American Society of Clinical Oncology (ASCO). This enhancement is designed to provide more comprehensive genetic information to guide cancer treatment decisions, surveillance planning, and family risk assessment.</p>\n\n<p>Dale Muzzey, Ph.D., Chief Scientific Officer at Myriad Genetics, emphasized the importance of this expansion, stating, \"While many labs can detect DNA variants, it's the interpretation of those variants that truly impacts patient care and that is where Myriad excels.\" The company's focus on including genes that influence treatment decisions aligns with medical society recommendations, potentially strengthening Myriad's position in the competitive genetic testing market.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Myriad Genetics Soars 5% as MyRisk Cancer Test Expands to Include 15 New Actionable Genes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Myriad Genetics Soars 5% as MyRisk Cancer Test Expands to Include 15 New Actionable Genes\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-10 23:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Myriad Genetics (NASDAQ: MYGN) are soaring 5.00% in Monday's intraday trading session following the company's announcement of a significant expansion to its MyRisk® Hereditary Cancer Test. The molecular diagnostic testing leader has added 15 new clinically actionable genes to the test, bringing the total to 63 genes across more than 11 cancer types.</p>\n\n<p>The expanded MyRisk test now includes 100% of the genes strongly recommended by national oncology guidelines, including those from the National Comprehensive Cancer Network (NCCN) and the American Society of Clinical Oncology (ASCO). This enhancement is designed to provide more comprehensive genetic information to guide cancer treatment decisions, surveillance planning, and family risk assessment.</p>\n\n<p>Dale Muzzey, Ph.D., Chief Scientific Officer at Myriad Genetics, emphasized the importance of this expansion, stating, \"While many labs can detect DNA variants, it's the interpretation of those variants that truly impacts patient care and that is where Myriad excels.\" The company's focus on including genes that influence treatment decisions aligns with medical society recommendations, potentially strengthening Myriad's position in the competitive genetic testing market.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MYGN","symbol_name":"万基遗传","start_time":0,"source_url":"","article_id":"1118188568","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1118188568","pubTimestamp":1762787492,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Myriad Genetics (NASDAQ: MYGN) are soaring 5.00% in Monday's intraday trading session following the company's announcement of a significant expansion to its MyRisk® Hereditary Cancer Test....","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MYGN":"万基遗传"},"translate_title":"个股追踪|Myriad Genetics飙升5%，MyRisk癌症测试扩展至包括15个新的可操作基因","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MYGN":1},"content_text":"Shares of Myriad Genetics (NASDAQ: MYGN) are soaring 5.00% in Monday's intraday trading session following the company's announcement of a significant expansion to its MyRisk® Hereditary Cancer Test. The molecular diagnostic testing leader has added 15 new clinically actionable genes to the test, bringing the total to 63 genes across more than 11 cancer types.\nThe expanded MyRisk test now includes 100% of the genes strongly recommended by national oncology guidelines, including those from the National Comprehensive Cancer Network (NCCN) and the American Society of Clinical Oncology (ASCO). This enhancement is designed to provide more comprehensive genetic information to guide cancer treatment decisions, surveillance planning, and family risk assessment.\nDale Muzzey, Ph.D., Chief Scientific Officer at Myriad Genetics, emphasized the importance of this expansion, stating, \"While many labs can detect DNA variants, it's the interpretation of those variants that truly impacts patient care and that is where Myriad excels.\" The company's focus on including genes that influence treatment decisions aligns with medical society recommendations, potentially strengthening Myriad's position in the competitive genetic testing market.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1118188568","isCrawlerRequest":true}